Short answer
GRAIL, Inc. (GRAL) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026.
GRAIL, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing GRAIL’s financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q1 total revenue $40.8M, up 28%; Galleri revenue $39.8M, up 37%, with test volume up 50% to more than 56,000
- Adjusted gross profit $19.7M versus $14.3M; GAAP gross loss narrowed to $14.3M
- Net loss $93.2M and adjusted EBITDA $(79.9)M, highlighting continued substantial cash-burn risk
- Cash, equivalents, and short-term securities $823.1M at March 31, 2026, supporting continued commercialization and regulatory investment
- FDA accepted Galleri’s PMA for review; Epic integration expected by end-2026 could expand ordering access nationwide
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GRAIL, Inc. 8-K filings
Get the next GRAL 8-K as it lands
Follow GRAL for push alerts, or ask the research agent what this filing means.